文献速递真菌感染

决定侵袭性肺曲霉病何时更换一线治疗的难题

Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本文为致编辑的信,针对Slavin等人在《J Antimicrob Chemother》2022年发表的关于侵袭性曲霉病抗真菌治疗更换时机的观点文章进行回应。作者指出该文虽综合专家咨询委员会经验讨论了临床因素,但支持临床决策的高质量数据仍匮乏,并强调原文未充分涉及的若干重要问题在决定何时更换治疗中起重要作用。

要点

  • 支持侵袭性曲霉病治疗更换决策的高质量数据仍匮乏。
  • 原文未充分涉及的其他重要问题影响换药时机决策。
  • 原文基于专家咨询委员会经验讨论临床因素。

核心结论

  • 支持侵袭性曲霉病治疗更换决策的高质量数据仍匮乏,原文未充分涉及的若干重要问题在决定换药时机中起重要作用。

研究设计与样本

  • 致编辑的信,针对Slavin等人在J Antimicrob Chemother 2022年发表的关于侵袭性曲霉病抗真菌治疗更换时机的观点文章进行回应。

主要发现

  • 原文综合专家咨询委员会经验讨论了驱动侵袭性曲霉病抗真菌治疗更换的多种临床因素。
  • 原文未充分涉及的其他重要问题在决定换药时机中起重要作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We read the excellent viewpoint by Slavin et al. (J Antimicrob Chemother 2022; 77: 16-23) that draws upon the experience of an advisory board of notable experts to comprehensively address many of the clinical factors that drive the need for changes in antifungal therapy for invasive aspergillosis (IA). As noted by the authors, there remains a paucity of quality data to support many of the decisions faced by clinicians managing patients with IA. However, we would like to highlight several other important issues, not fully addressed in that viewpoint, that play an important role in deciding when to change antifungal therapy for IA.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Colombo AL, De Almeida JN, Lewis RE, et al. Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis. J Antimicrob Chemother. 2022. PMID: 36059133. doi:10.1093/jac/dkac301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。